Dynavax Technologies Corp.

NASDAQ:DVAX  
9.47
-0.24 (-2.47%)
5:05:11 PM EDT: $9.50 +0.03 (+0.32%)
Products, Other Pre-Announcement

Clover And Dynavax Announce Commercial Supply Agreement Of Dynavax's CpG 1018 Adjuvant For Clover's COVID-19 Vaccine Candidate

Published: 06/30/2021 08:12 GMT
Dynavax Technologies Corp. (DVAX) - Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's Cpg 1018 Adjuvant for Clover's Covid-19 Vaccine Candidate.
Clover Biopharmaceuticals-commercial Supply Agreement Extends to End of 2022.
Clover Biopharmaceuticals- Pending Conditional Regulatory Approvals, Co Expects to Commence Product Launch of Scb-2019 (cpg 1018/alum) by End of 2021.